REVLIMID® (lenalidomide) in combination with a rituximab product is indicated for the treatment of adult patients with previously treated follicular lymphoma (FL). REVLIMID in combination with a rituximab product is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL). REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

IN THE ITT POPULATION (N=358)

Dose modifications were typically due to TEAEs18

Dose modifications for REVLIMID® (lenalidomide) and rituximab

Dose modifications may help patients stay on therapy.1

Starting dose modifications for renal impairment1

RENAL IMPAIRMENT

Dose Modifications for Renal Impairment
  • 13% of patients (n=48) in the AUGMENT trial had renal impairment and received a starting dose of 10 mg once daily18
    • For patients with a CrCI of 30 to <60 mL/min after 2 cycles, the REVLIMID dose may be increased to 15 mg orally, if the patient has tolerated therapy1

Dose modifications for grade 3/4 Neutropenia1

NEUTROPENIA

Dose Modifications for Neutropenia
  • For non-hematologic Grade 3/4 toxicities judged to be related to REVLIMID, hold treatment and restart at the physician’s discretion at next lower dose level when toxicity has
    resolved to Grade 2 or below
  • REVLIMID must be discontinued for angioedema, Grade 4 rash, exfoliative or bullous rash, or if Stevens-Johnson syndrome, toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic symptoms is suspected and should not be resumed following discontinuation for these reactions

DOSE MODIFICATIONS FOR GRADE 3/4 THROMBOCYTOPENIA1

THROMBOCYTOPENIA

Dose Modifications for Thrombocytopenia
  • For non-hematologic Grade 3/4 toxicities judged to be related to REVLIMID, hold treatment and restart at the physician’s discretion at next lower dose level when toxicity has resolved to Grade 2 or below
  • REVLIMID must be discontinued for angioedema, Grade 4 rash, exfoliative or bullous rash, or if Stevens-Johnson syndrome, toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic symptoms is suspected and should not be resumed following discontinuation for these reactions

CBC, complete blood count; CrCl, creatinine clearance; ITT, intent-to-treat;
TEAE, treatment-emergent adverse event.

See full reference list.